Catheter-related bloodstream infection market outlook with growth drivers
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Much Will The Market Value Of The Catheter-Related Bloodstream Infection Market Grow Between 2026 And 2030?
The catheter-related bloodstream infection market has seen substantial growth in recent years. It is anticipated to expand from $1.62 billion in 2025 to $1.71 billion in 2026, reflecting a compound annual growth rate (CAGR) of 6.0%. This market’s past expansion can be attributed to the increased deployment of central venous catheters, a growing prevalence of hospital-acquired infections, the implementation of antibiotic lock therapy, the enlargement of intensive care facilities, and enhanced clinical understanding of crbsi.
The catheter-related bloodstream infection market size is projected to experience robust expansion in the coming years. This market is set to reach $2.11 billion in 2030, growing at a compound annual growth rate (CAGR) of 5.3%. The forecasted growth can be attributed to various factors such as increasing investments in infection prevention protocols, a rising demand for antimicrobial resistance management, the expansion of hospital infection control programs, a growing adoption of combination therapies, and advancements in diagnostic technologies. Significant trends within the forecast period include a greater use of advanced antimicrobial lock solutions, increasing adoption of infection surveillance programs, a heightened focus on preventing hospital-acquired infections, the proliferation of combination antimicrobial therapies, and an enhanced emphasis on early diagnosis and intervention.
Access Your Free Sample Report For In-Depth Market Analysis:
Which Factors Are Influencing The Growth Of The Catheter-Related Bloodstream Infection Market?
The increasing occurrence of hospital-acquired infections is anticipated to boost the expansion of the catheter-related bloodstream infection market. HAIs are infections contracted by patients in healthcare settings while receiving treatment for other ailments, typically emerging 48 hours or more after admission. Factors like antimicrobial resistance, insufficient infection control, and patient vulnerability contribute to the rise in these infections. Catheter-related bloodstream infections are a major component of HAIs because of their invasive nature and potential for microbial growth, presenting risks to individuals with catheters. For example, the National Library of Medicine reported in September 2025 that in 2024, antimicrobial-resistant organisms constituted 6.6% of infections. Approximately one-third of healthcare-associated infections were associated with medical devices, and the incidence of central line-associated bloodstream infections surged to 0.4%. Consequently, the increasing incidence of hospital-acquired infections will fuel the growth of the catheter-related bloodstream infection market. The expansion of the catheter-related bloodstream infection market is anticipated to be driven by increasing healthcare expenditure. Healthcare expenditure signifies the total financial investment made by individuals, organizations, or governments towards the prevention, treatment, and management of health conditions. This spending is growing due to progress in medical technology, where advanced diagnostic tools, treatments, and innovative therapies often entail higher expenses, thereby raising overall healthcare costs. Higher healthcare spending contributes to reducing catheter-related bloodstream infections by financing preventative actions, staff education, surveillance systems, and prompt medical care, ultimately enhancing patient results and decreasing overall expenses. For instance, the Centers for Medicare & Medicaid Services reported in December 2024 that U.S. health care expenditures rose by 7.5% in 2023, reaching $4.9 trillion, equivalent to approximately $14,570 per person. Consequently, the escalating healthcare expenditure is fostering the growth of the catheter-related bloodstream infection market.
What Are The Main Segments Within The Catheter-Related Bloodstream Infection Market Segment Structure?
The catheter-related bloodstream infection market covered in this report is segmented –
1) By Treatment: Antibiotic Lock Therapy, Anti-Microbial Agents
2) By Source Of Infection Or Causative Agents: Staphylococcus Aureus, Acinetobacter Baumannii, Escherichia Coli (E. Coli), Klebsiella Pneumoniae (K. Pneumonia), Candida Species (Candida Sp.), Pseudomonas Aeruginosa (P. Aeruginosa), Other Source Of Infection Or Causative Agents
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies
Subsegments:
1) By Antibiotic Lock Therapy: Catheter Lock Solutions (Antibiotic-based), Combination Antibiotic Lock Therapy
2) By Anti-Microbial Agents: Antibiotics, Antifungal Agents, Antiseptic Agents
Which Trends Are Influencing Demand In The Catheter-Related Bloodstream Infection Market?
Leading companies in the catheter-related bloodstream infection market are developing innovative catheter lock solutions to enhance infection prevention and improve patient outcomes. A catheter lock solution is a liquid introduced into a catheter to prevent infections and maintain its patency between uses. For instance, in November 2023, CorMedix Inc., a US-based biopharmaceutical company focused on developing and commercializing therapeutic products, received US Food and Drug Administration approval for DefenCath (taurolidine and heparin) catheter lock solution for adult patients with kidney failure undergoing chronic hemodialysis via central venous catheter (CVC). This antimicrobial and antifungal solution is designed to reduce catheter-related bloodstream infections (CRBSIs), combining heparin for anticoagulation with taurolidine’s broad-spectrum antimicrobial properties.
Who Are The Companies Participating In The Catheter-Related Bloodstream Infection Market?
Major companies operating in the catheter-related bloodstream infection market are Pfizer Inc., Johnson & Johnson Services Inc., Novartis AG, 3M Company, Eli Lilly and Company, Fresenius Medical Care AG & Co. KGaA, Becton Dickinson and Company, Viatris Inc., B. Braun Medical Inc., Aurobindo Pharma Limited, Lupin Ltd., Xellia Pharmaceuticals Ltd., SteriMax Inc., Bactiguard AB, Hetero Healthcare Ltd., TauroPharm GmbH, Advacare Pharma, Citus Pharmaceuticals Inc., CorMedix Inc., JoinHub Pharma LLP, IntegraDose Compounding Services LLC
Get The Full Catheter-Related Bloodstream Infection Market Report:
Which Region Dominates The Catheter-Related Bloodstream Infection Market By Market Share?
North America was the largest region in the catheter-related bloodstream infection market in 2025. The regions covered in the catheter-related bloodstream infection market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Catheter-Related Bloodstream Infection Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Catheter-Related Bloodstream Infection Market 2026, By The Business Research Company
Catheters Market Report 2026
https://www.thebusinessresearchcompany.com/report/catheters-global-market-report
Diagnostic Catheters Market Report 2026
https://www.thebusinessresearchcompany.com/report/diagnostic-catheters-global-market-report
Pediatric Catheter Market Report 2026
https://www.thebusinessresearchcompany.com/report/pediatric-catheter-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.
